Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

April 14, 2023

Julia E. McGuinness, MD, discusses the rationale for combining this novel PI3K inhibitor with fulvestrant and emphasized the importance of developing increasingly mutant-specific PI3K inhibitors in hormone receptor–positive breast cancer.

March 22, 2023

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.

March 20, 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

February 16, 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

February 07, 2023

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

December 23, 2022

Richard D. Carvajal, MD, discusses the implications of the FDA approval of tebentafusp in uveal melanoma, the possibility of exploring tebentafusp in other HLA subtypes, and other areas of intriguing research in uveal melanoma.

December 13, 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

October 20, 2022

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological determinants on cancer risk.

October 20, 2022

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

October 20, 2022

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.

July 24, 2022

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

July 24, 2022

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

July 11, 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

July 08, 2022

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

June 24, 2022

The combination of amivantamab-vmjw and lazertinib produced encouraging responses with acceptable safety in patients with EGFR-mutated non–small cell lung cancer who progressed on osimertinib and platinum-based chemotherapy.

June 16, 2022

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

May 19, 2022

Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.

January 06, 2022

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

December 18, 2021

Steven L. Spitalnik, MD, discusses the evolution of red blood cell storage and the potential impact the Hemanext storage technique could have for patients with hematologic malignancies.

December 08, 2021

Steven L. Spitalnik, MD, discusses the goals for the Hemanext® blood storage system in patients with hematologic malignancies.